X-linked myopathy with excessive autophagy, known as XMEA, is an extraordinarily rare neuromuscular disorder that affects almost exclusively males, with no affected females reported to date. Symptoms most often begin in childhood, though congenital and late-onset cases have been described. Patients experience slowly progressive weakness of the proximal muscles, typically starting in the lower limbs and gradually spreading, frequently leading to loss of the ability to walk by mid-adulthood. Although the condition has traditionally been viewed as confined to skeletal muscle, growing clinical evidence points to respiratory involvement as relatively common, and cardiac abnormalities have been documented in a subset of patients.

The root cause of XMEA lies in mutations in a gene called Vma21, which encodes an essential assembly chaperone for the vacuolar H⁺-ATPase, or V-ATPase, the principal proton pump responsible for acidifying lysosomes, the membrane-bound compartments that serve as the cell’s digestive and recycling machinery. Lysosomes require a highly acidic interior to activate the hydrolytic enzymes that break down cellular cargo. When Vma21 is deficient, V-ATPase complexes fail to assemble properly, lysosomal acidification falters, and undegraded autophagic material accumulates in muscle fibers as characteristic vacuoles. Under the microscope, muscle biopsies from patients display cytoplasmic vacuoles studded with sarcolemmal and basal lamina proteins, complex fiber splitting, deposition of the complement membrane attack complex C5b-9, and, in some cases, aggregates of autophagy receptors such as SQSTM1/p62. Two features in particular, reduplication of the basal lamina and so-called autophagic vacuoles with sarcolemmal features, structures bounded by membranes normally found at the muscle cell surface, define the disease and distinguish it from the related Danon disorder, which arises from loss of the lysosomal membrane protein LAMP2.

Despite the identification of Vma21 as the culprit gene, researchers have struggled to explain precisely how its deficiency drives progressive muscle degeneration, largely because no mammalian model reliably reproduced the disease’s hallmark structural features. A recently described zebrafish model, for instance, showed autophagic impairment but failed to develop the signature vacuoles and basal lamina abnormalities. The new study closes that gap with two complementary mouse models generated using the CRISPR-Cas9 system to insert loxP sites flanking the X-linked Vma21 gene, enabling conditional deletion with Cre recombinase.

The first model employed the muscle creatine kinase promoter to delete Vma21 in both skeletal and cardiac muscle from early development. Because Vma21 resides on the X chromosome, male mice were used to guarantee complete gene inactivation. The result was dramatic: mice lacking Vma21 in both striated muscles were born at expected frequencies but grew poorly and died uniformly between postnatal days 22 and 23. Histological examination revealed that the lethality stemmed not from skeletal muscle but from the heart. While the skeletal muscles of these animals showed no evident myopathy at the time of death, their hearts displayed severe cardiomyopathy, with inflammatory infiltration and extensive cytoplasmic vacuolization. Echocardiography at postnatal day 18 confirmed markedly impaired contractile function, with reduced fractional shortening and elevated filling pressures, identifying heart failure as the cause of death. Biochemical analysis of cardiac tissue revealed the accumulation of LAMP2, poly-ubiquitinated proteins, LC3B-II, and SQSTM1, the molecular fingerprint of stalled autophagy, while skeletal muscle at the same age showed no significant changes in bulk autophagy markers.

The researchers interpret this striking cardiac vulnerability in light of the genetics of human XMEA. In patients, pathogenic variants reduce but do not abolish Vma21 transcript production, leaving residual protein function in what is termed a hypomorphic mechanism. The knockout mice, by contrast, suffer near-complete loss of the protein, and the findings suggest that cardiac muscle tolerates profound autophagic impairment far less well than skeletal muscle. A parallel can be drawn with Danon disease, in which LAMP2 deficiency produces severe cardiomyopathy alongside skeletal muscle pathology. The authors note that emerging clinical reports of cardiac abnormalities in some XMEA patients suggest cardiac involvement may be underrecognized, and they underscore the importance of systematic cardiac evaluation in affected individuals, even though cardiac disease is relatively uncommon in the human condition.

To capture the skeletal muscle disease without the confounding early lethality, the team engineered a second model in which Vma21 deletion is restricted to skeletal muscle and can be triggered at will in adult animals using a tamoxifen-inducible Cre recombinase under the control of the human skeletal actin promoter. After two months of tamoxifen treatment, Vma21 protein was robustly depleted from the tibialis anterior, gastrocnemius, and quadriceps muscles, while expression in heart, liver, and kidney remained untouched. The mice began losing weight relative to controls, and by four months they showed significantly reduced grip endurance, a functional echo of the progressive weakness seen in patients.

The histological story unfolded gradually. At two months, despite efficient Vma21 loss, the muscle looked essentially normal. At three months, fibers of increasingly variable size appeared, along with early fiber splitting and nuclei migrating to the center of fibers, a classic sign of muscle pathology. By four months the changes were unmistakable, and at six months they had intensified, with quantification confirming significant increases in the percentage of fibers with internalized nuclei, the percentage of fibers exhibiting splitting, and the coefficient of variation of fiber cross-sectional area. The delayed onset carries its own biological message. Mature muscle fibers possess unusually long-lived lysosomes, the authors suggest, and those assembled before Vma21 deletion may continue functioning for weeks, masking the defect until newly formed, improperly acidified lysosomes gradually accumulate and overwhelm the fiber’s degradative capacity.

Molecular analyses of the myopathic muscle confirmed autophagic dysregulation. Levels of LAMP2, poly-ubiquitinated proteins, and LC3B-II rose substantially by four months, yet messenger RNA levels for LC3B and SQSTM1 were unchanged, demonstrating that the protein buildup reflects failed degradation rather than increased production. Immunofluorescence revealed LAMP2, LC3B, SQSTM1, and poly-ubiquitin-positive puncta clustered conspicuously at the periphery of muscle fibers. Crucially, co-staining for laminin and dystrophin exposed both basal lamina reduplication and authentic autophagic vacuoles with sarcolemmal features, vacuoles that carried lysosomal and autophagy markers within their lumens. Transmission electron microscopy then revealed the fine structure: membrane-bound vacuoles containing partially undegraded electron-dense material, frequently piled up in the subsarcolemmal region, alongside irregular membrane regions studded with clusters of small vesicles, some of which had apparently escaped into the extracellular space.

It was this last observation that led the team to an entirely new discovery. Reasoning that peripheral vacuole accumulation might reflect increased exocytosis of undegraded material, they examined CD63, a marker of late endosomes and exosomes. Control muscle showed minimal CD63 staining, but Vma21-deficient fibers were studded with CD63-positive structures enriched at their periphery. Remarkably, these structures colocalized strongly with the complement membrane attack complex C5b-9 at the sarcolemma. When the researchers turned to stored muscle biopsies from genetically confirmed XMEA patients, they found the same pattern: increased CD63 staining colocalizing with C5b-9, indicating that this feature is conserved between mouse and human disease. Complement deposition has been recognized in XMEA muscle for years, but its origin has remained mysterious. The new findings raise the possibility that altered vesicle trafficking or the exposure of vesicle-associated components at the fiber surface recruits the complement cascade, forging a mechanistic link between failed autophagy, disturbed membrane traffic, and inflammatory attack on muscle fibers.

The sarcolemmal C5b-9 deposition also suggests an immediate therapeutic avenue. Complement inhibition with the C5 blocker eculizumab has recently been reported to improve clinical measures in a patient with dysferlinopathy, another muscle disease marked by complement deposition at the muscle membrane. Although the triggers of complement activation may differ between the two disorders, the authors propose that complement-directed therapies could now be tested directly in their Vma21-deficient mice to determine whether the complement system actively drives disease progression in XMEA.

The study is not without limitations. The knockout models achieve near-complete loss of Vma21, whereas most patients retain partial function; only male mice were analyzed, leaving open questions about X-chromosome inactivation and sex-specific severity in females; and the precise temporal relationship among autophagic failure, vesicle trafficking changes, membrane remodeling, and weakness remains to be fully mapped, as does the question of whether altered vesicle traffic drives disease or represents a compensatory response. Even so, the models constitute a robust mammalian platform that reproduces the progressive myopathy, autophagic dysregulation, sarcolemmal vacuoles, and basal lamina reduplication that define XMEA. For a disease that has lacked both animal models and treatment options, the work offers researchers, for the first time, a physiologically relevant system in which to dissect mechanisms and screen disease-modifying therapies, along with a fresh biological target, the CD63-positive vesicle pathway and its uneasy partnership with complement, that may prove central to how this rare muscle disease takes its toll.

The story began when a young boy from Alabama underwent comprehensive whole-genome sequencing, which revealed a mutation in the VMA21 gene. This gene is conclusively linked to XMEA, and its mutation disrupts essential cellular processes involving lysosomal function. Leading pediatric neurologist Dr. Michael Lopez from the University of Alabama at Birmingham recognized the potential this finding held and referred the family to the university’s Center for Precision Animal Modeling (C-PAM). This specialized center focuses on the generation of precise animal models that recapitulate human genetic diseases.

Collaborating across borders, UAB’s Dr. Matthew Alexander and Toronto’s Dr. Jim Dowling spearheaded the development of a novel zebrafish model by inducing targeted mutations in the fish gene analogous to human VMA21, utilizing CRISPR-Cas9, the revolutionary genome-editing technology known as molecular scissors. Through precise deletion and insertion mutations, they created two distinct VMA21 loss-of-function zebrafish strains. These mutations mimic the pathological conditions observed in XMEA by significantly reducing the levels of functional VMA21 protein, which plays a crucial role in acidifying lysosomes—a vital step in autophagy, the cell’s mechanism for recycling damaged components.

The mutant zebrafish displayed dramatic phenotypic traits reflecting the human condition, such as shortened body length and underdeveloped swim bladders, both indicative of muscle dysfunction. Behavioral assays revealed a markedly impaired swimming response; the zebrafish were less capable of evading stimuli and exhibited reduced activity and locomotion compared to their wild-type counterparts. These observable defects underscore the profound effect that VMA21 mutations exert on muscle structure and function in vivo.

A fundamental cellular pathology shared between the fish model and patients with XMEA centers on the defective autophagy pathway. In healthy cells, lysosomes maintain an acidic environment that activates proteolytic enzymes responsible for degrading and recycling cellular debris. The VMA21 mutation compromises lysosomal acidification, leading to the accumulation of vacuoles—membrane-bound fluid-filled structures within muscle cells—hallmarks of the disease. Additionally, mutant fish exhibited liver and cardiac abnormalities, paralleling the multi-organ impact of XMEA in humans.

Importantly, while the mutant zebrafish displayed severe phenotypes and reduced lifespans—likely attributable to a more complete abrogation of VMA21 function compared to human patients—this robust presentation provided an accelerated window into disease progression. The researchers capitalized on these attributes to conduct an expansive drug screen, probing the therapeutic potential of thirty autophagy-modulating compounds sourced from the Selleckchem library. This screening capitalized on quantifiable changes in muscle birefringence, a property whereby altered muscle fiber organization affects the refraction of polarized light, providing a sensitive readout of muscular integrity.

Out of the thirty screened drugs, nine candidates emerged with promising capacity to reduce aberrant muscle birefringence and extend survival in the mutant zebrafish. Further long-term functional assays narrowed this to two potent compounds—edaravone and LY294002—that consistently ameliorated the mutant phenotype across multiple metrics including muscle structure, motor function, and overall lifespan. Edaravone, a radical scavenger, and LY294002, a PI3 kinase inhibitor known to influence autophagic pathways, demonstrated efficacy by modulating the impaired autophagy characteristic of VMA21 deficiency.

These findings highlight the central role autophagy modulation could play in counteracting the pathological cascade initiated by defective lysosomal acidification. They provide compelling evidence that pharmacological antagonists of autophagy possess the potential not merely to attenuate symptoms but to modify disease progression in XMEA. The zebrafish model’s high degree of fidelity to human pathology lends considerable translational weight to these observations, offering a promising preclinical platform for drug validation.

Building on this success with the zebrafish, the research team is now advancing studies into mammalian models, specifically genetically engineered mice harboring the VMA21 mutation. This step is critical to validate the therapeutic promise of identified compounds in organisms closer to humans and to comprehensively delineate the disease mechanisms at play across different biological systems. The mouse model will facilitate detailed investigation of tissue-specific effects and long-term outcomes, further driving efforts toward clinical application.

This research not only sheds light on the intricate molecular underpinnings of an ultra-rare disease but also exemplifies the power of precision animal modeling combined with genetic editing technologies. It opens a new frontier where zebrafish, a surprisingly apt miniature vertebrate with transparent larvae and rapid life cycles, serve as a versatile and scalable platform for drug discovery against conditions that have hitherto been refractory to study.

Dr. Alexander succinctly captured the significance of the work: “We have established the first preclinical animal model of XMEA, and we have determined that this model faithfully recapitulates most features of the human disease. It thus is ideally suited for establishing disease pathomechanisms and identifying therapies.” These words echo the transformative impact of merging state-of-the-art molecular biology with innovative animal research—a beacon of hope for individuals affected by XMEA and other rare genetic myopathies.

Ultimately, the convergence of genome sequencing, CRISPR gene editing, and targeted drug screening in zebrafish arrives at a rare intersection of basic science and translational medicine. It underscores the potential to unlock novel therapeutic avenues where none previously existed, charting a path toward informed, mechanism-based treatments tailored to the unique genetic profiles of rare disease patients. As this research advances into clinical trials, it carries the promise not only of improved outcomes for XMEA patients but a blueprint for tackling other orphan diseases through precision model organisms.

Subject of Research: Animals
Article Title: X-linked myopathy with excessive autophagy: characterization and therapy testing in a zebrafish model
News Publication Date: Not explicitly stated; inferred April 19, 2025 (article publication date)
Web References: https://doi.org/10.1038/s44321-025-00204-8
References: EMBO Molecular Medicine, Volume and issue not specified (April 19, 2025)
Keywords: Genetic disorders, Genetic testing, Zebrafish